Log in
NASDAQ:ABCM

Abcam Stock Forecast, Price & News

$19.01
+0.05 (+0.26 %)
(As of 12/4/2020 04:45 PM ET)
Add
Compare
Today's Range
$18.85
Now: $19.01
$19.24
50-Day Range N/A
52-Week Range
$17.71
Now: $19.01
$20.87
Volume40,312 shs
Average Volume200,007 shs
Market Capitalization$4.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABCM
CUSIPN/A
CIKN/A
Phone44 1223 696 000
Employees1,492

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$4.28 billion
Next Earnings DateN/A
OptionableNot Optionable
$19.01
+0.05 (+0.26 %)
(As of 12/4/2020 04:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABCM News and Ratings via Email

Sign-up to receive the latest news and ratings for ABCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abcam (NASDAQ:ABCM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Abcam?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Abcam
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Abcam?

Wall Street analysts have given Abcam a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abcam wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for ABCM?

5 brokers have issued 12-month target prices for Abcam's shares. Their forecasts range from $20.00 to $22.00. On average, they expect Abcam's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price.
View analysts' price targets for Abcam
.

Who are some of Abcam's key competitors?

Who are Abcam's key executives?

Abcam's management team includes the following people:
  • Mr. Alan Thomas Hirzel BS, MS, MBA, CEO & Exec. Director (Age 52)
  • Mr. Michael Shaun Baldock, CFO & Director (Age 54)
  • Mr. Mark Dermody, Interim CIO
  • James Staveley, VP of Investor Relations
  • Marc Perkins, Associate Gen. Counsel & Company Sec.
  • Dr. Cheri L. Walker, Sr. VP of Corp. Devel.
  • Mr. Nick Skinner, Sr. VP of HR
  • Mr. Mark Bushfield, Sr. VP of Research & Innovation
  • Ms. Kirstie Speck BBusSc, Head of Consumer Insights
  • Ms. Yvonne Chien, Sr. VP of Customer Experience

When did Abcam IPO?

(ABCM) raised $149 million in an IPO on Thursday, October 22nd 2020. The company issued 9,000,000 shares at a price of $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO.

What is Abcam's stock symbol?

Abcam trades on the NASDAQ under the ticker symbol "ABCM."

When did the company's quiet period expire?

Abcam's quiet period expired on Tuesday, December 1st. Abcam had issued 8,945,218 shares in its initial public offering on October 22nd. The total size of the offering was $156,541,315 based on an initial share price of $17.50. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Abcam?

Shares of ABCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abcam's stock price today?

One share of ABCM stock can currently be purchased for approximately $19.01.

How big of a company is Abcam?

Abcam has a market capitalization of $4.28 billion. Abcam employs 1,492 workers across the globe.

What is Abcam's official website?

The official website for Abcam is www.abcam.com.

How can I contact Abcam?

The company can be reached via phone at 44 1223 696 000.

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.